

Serum and pleural soluble cell adhesion molecules in mesothelioma patients: a retrospective cohort study

SUPPLEMENTARY FILE

Table S1. Disease progression relative to demographics, clinical characteristics and serum and pleural soluble cell adhesion molecules levels in 92 mesothelioma patients. (Results derived from univariate analysis).

Variables			
Baseline characteristics		HR (95% CI)	P
Gender	Male (ref)		
	Female	0.90 (0.31-2.62)	0.843
Age		1.01 (0.96-1.05)	0.724
Smoker	No (ref)		
	Yes	0.82 (0.37-1.8)	0.623
Asbestos exposure	No (ref)		
	Yes	0.66 (0.29-1.5)	0.322
Weight loss > 10%	No (ref)		
	Yes	1.74 (0.74-4.06)	0.204
Performance Status		2.35 (1.33-4.14)	0.003
Stage		1.24 (0.92-1.66)	0.651
Initial presenting symptom			
Cough	No (ref)		
	Yes	0.8 (0.3-2.13)	0.651
Dyspnea	No (ref)		
	Yes	2.31 (1.04-5.16)	0.041
Thoracic pain	No (ref)		
	Yes	0.64 (0.29-1.43)	0.281
Grade	High (ref)		
	Low	0.63 (0.26-1.49)	0.291
Radiation Therapy	No (ref)		
	Yes	1.62 (0.58-4.54)	0.361
Cancer location and spread on time of diagnosis			
Pleura	No (ref)		
	Right	0.36 (0.05-2.78)	0.328
	Left	0.37 (0.05-3.04)	0.357
	Bilateral	0.3 (0.03-3.42)	0.336
Pericardium	No (ref)		
	Yes	0.96 (0.29-3.22)	0.951
Peritoneum	No (ref)		
	Yes	1.55 (0.36-6.6)	0.555
Bones	No (ref)		
	Yes	1.36 (0.53-3.45)	0.519
Lymph nodes	No (ref)		
	Yes	1.31 (0.52-3.3)	0.563
Lung	No (ref)		
	Yes	1.18 (0.53-2.6)	0.686
Liver	No (ref)		
	Yes	2.44 (0.72-8.3)	0.154
Another organ	No (ref)		

	Yes	1.03 (0.24-4.37)	0.969
Cancer location and spread on follow up			
Pleura	No (ref)		
	Yes	21.16 (0-299.79)	0.614
Pericardium	No (ref)		
	Yes	0.80 (0.18-3.5)	0.767
Peritoneum	No (ref)		
	Yes	0.04 (0.00-21.17)	0.315
Bones	No (ref)		
	Yes	0.82 (0.29-2.28)	0.705
Lymph nodes	No (ref)		
	Yes	3.99 (1.49-10.66)	0.006
Lung	No (ref)		
	Yes	2.91 (1.02-8.3)	0.045
Liver	No (ref)		
	Yes	1.54 (0.5-4.72)	0.453
Brain	No (ref)		
	Yes	5.69 (0.73-44.46)	0.097
Other organ	No (ref)		
	Yes	0.04 (0.0-84.54)	0.416
Soluble cell adhesion molecules serum and pleural levels (ng/ml)		<i>HR (95% CI)*</i>	<i>P</i>
sE-CADHERIN serum		0.98 (0,9-1.07)	0.644
sE-CADHERIN pleural		1.08 (1,01-1.17)	0.043
sE-SELECTIN serum		0.92 (0,81-1.04)	0.193
sE-SELECTIN pleural		0.96 (0,84-1.09)	0.514
sICAM serum		0.99 (0,96-1.03)	0.6
sICAM pleural		1.02 (0,98-1.05)	0.343
sVCAM serum		1.00 (0,95-1.06)	0.884
sVCAM pleural		0.96 (0,89-1.02)	0.197

HR (95% CI), hazard ratio (95% confidence intervals); sICAM, soluble intercellular adhesion molecules; ref, reference; sVCAM, soluble vascular cell adhesion molecules

*per 10 units of increase

Table S2. Mortality relative to demographics, clinical characteristics and serum and pleural cell adhesion molecules levels in 92 mesothelioma patients. (Results derived from univariate analysis).

Variables			
Baseline characteristics		HR (95% CI)	P
Gender	Male (ref)		
	Female	0.65 (0.33-1.27)	0.204
Age		1.02 (0.99-1.04)	0.197
Smoker	No (ref)		
	Yes	1.31 (0.79-2.15)	0.293
Asbestos exposure	No (ref)		
	Yes	1.05 (0.63-1.73)	0.861
Weight loss > 10%	No (ref)		
	Yes	2.47 (1.37-4.47)	0.003
Performance Status		2.47 (1.64-3.72)	<0.001
Stage		1.36 (1.13-1.62)	0.001
Initial presenting symptom			
Cough	No (ref)		
	Yes	0.94 (0.53-1.67)	0.844
Dyspnea	No (ref)		
	Yes	1.06 (0.65-1.75)	0.810
Thoracic pain	No (ref)		
	Yes	1.22 (0.75-1.97)	0.425
Grade	High (ref)		
	Low	0.56 (0.33-0.94)	0.028
Radiation Therapy	No (ref)		
	Yes	0.67 (0.34-1.32)	0.245
Cancer location and spread on time of diagnosis			
Pleura	No (ref)		
	Right	0.23 (0.03-1.79)	0.162
	Left	0.23(0.03-1.77)	0.157
	Bilateral	0.18(0.02-1.58)	0.121
Pericardium	No (ref)		
	Yes	1.5 (0.68-3.32)	0.317
Peritoneum	No (ref)		
	Yes	4.37 (1.82-10.48)	0.001
Bones	No (ref)		
	Yes	3.86 (2.04-7.32)	<0.001
Lymph nodes	No (ref)		
	Yes	2.04 (1.11-3.75)	0.022
Lung	No (ref)		
	Yes	1.1 (0.67-1.79)	0.714
Liver	No (ref)		
	Yes	8.28 (3.14-21.86)	<0.001
Another organ	No (ref)		
	Yes	2.67 (1.18-6.02)	0.018
Cancer location and spread on follow up			
Pleura	No (ref)		
	Yes	1.04 (0.14-7.61)	0.971
Pericardium	No (ref)		
	Yes	1.07 (0.5-2.29)	0.860
Peritoneum	No (ref)		

	Yes	0.96 (0.41-2.28)	0.933
Bones	No (ref)		
	Yes	1.49 (0.84-2.64)	0.170
Lymph nodes	No (ref)		
	Yes	1.37 (0.77-2.44)	0.291
Lung	No (ref)		
	Yes	0.7 (0.39-1.25)	0.231
Liver	No (ref)		
	Yes	1.22 (0.6-2.48)	0.587
Brain	No (ref)		
	Yes	0.66 (0.09-4.85)	0.684
Other organ	No (ref)		
	Yes	0.77 (0.27-2.17)	0.622
Soluble cell adhesion molecules serum and pleural levels (ng/ml)		<i>HR (95% CI) *</i>	<i>P</i>
sE-CADHERIN serum		0.96 (0.91-1.02)	0.168
sE-CADHERIN pleural		1.03 (0.98-1.09)	0.235
sE-SELECTIN serum		0.95 (0.88-1.03)	0.231
sE-SELECTIN pleural		0.94 (0.87-1.02)	0.139
sICAM serum		0.99 (0.96-1.01)	0.235
sICAM pleural		1.01 (0.99-1.03)	0.501
sVCAM serum		1.00 (0.96-1.03)	0.895
sVCAM pleural		0.99 (0.96-1.03)	0.707

HR (95% CI), hazard ratio (95% confidence intervals); sICAM, soluble intercellular adhesion molecules; ref, reference; sVCAM, soluble vascular cell adhesion molecules

*per 10 units of increase




Figure S1. Kaplan-Meier plot demonstrating disease progression per performance status group.




Figure S2. Kaplan-Meier plot demonstrating mortality per performance status group.